Table 4.
Clinical characteristics and metabolic profile of GALNT2 rs4846914 genotypes in overweight/obese and non-obese GDM patients.
| Overweight/Obese GDM | Non-obese GDM | |||||
|---|---|---|---|---|---|---|
| GG (197) | GA (110) | AA (23) | GG (74) | GA (46) | AA (11) | |
| Clinical characteristics | ||||||
| Age (years) | 35.85 ± 3.11 | 34.75 ± 4.11 | 35.29 ± 4.15 | 36.08 ± 4.08 | 32.34 ± 4.54 | 33.44 ± 4.42 |
| Gestation age (weeks) | 39.08 ± 0.82 | 38.97 ± 0.90 | 39.17 ± 0.65 | 38.91 ± 1.25 | 39.18 ± 0.65 | 39.10 ± 0.75 |
| Prepregnancy BMI (kg/m2) | 23.58 ± 3.01 | 23.5 ± 3.65 | 23.3 ± 2.52 | 19.72 ± 1.07 | 18.81 ± 1.52 | 19.29 ± 1.39 |
| Weight gain during pregnancy (kg) | 11.29 ± 4.12 | 12.38 ± 4.50 | 12.25 ± 4.52 | 9.13 ± 4.22 | 11.54 ± 2.67 | 10.76 ± 3.85 |
| Delivery BMI (kg/m2) | 29.19 ± 6.43 | 28.43 ± 3.72 | 28.09 ± 2.29 | 23.39 ± 1.10 | 23.33 ± 1.34 | 23.55 ± 1.04 |
| Neonatal birth height (cm) | 49.83 ± 1.81 | 49.95 ± 1.62 | 49.00 ± 1.62a,* | 49.28 ± 1.55 | 49.44 ± 1.97 | 49.25 ± 2.42 |
| Neonatal birth Weight (g) | 3358.02 ± 385.86 | 3366.44 ± 368.25 | 3194.38 ± 406.11a,* | 3172.21 ± 352.45 | 3171.09 ± 349.97 | 3330.91 ± 411.96 |
| SBP (mmHg) | 114.69 ± 8.80 | 116.96 ± 11.33 | 116.19 ± 12.79 | 112.24 ± 9.41 | 113.79 ± 9.45 | 119.58 ± 10.87a,* |
| DBP (mmHg) | 73.84 ± 9.13 | 73.05 ± 9.93 | 73.22 ± 9.21 | 70.69 ± 7.81 | 74.43 ± 9.41 | 79.17 ± 9.51a,** |
| Metabolic profile | ||||||
| Fasting Ins (pmol/L) | 89.24 ± 58.83 | 88.95 ± 56.12 | 101.61 ± 68.35 | 66.20 ± 45.06 | 81.14 ± 60.31 | 80.95 ± 55.38 |
| Fasting Glu (mmol/L) | 4.32 ± 0.52 | 4.47 ± 0.68 | 4.41 ± 0.79 | 4.67 ± 0.84 | 4.36 ± 0.96 | 4.37 ± 0.73 |
| HOMA-IR | 2.93 ± 2.16 | 3.18 ± 3.09 | 3.08 ± 3.74 | 3.55 ± 3.53 | 3.56 ± 4.50 | 2.53 ± 4.49 |
| Triglycerides (mmol/L) | 3.55 ± 1.16 | 4.12 ± 1.82 | 3.95 ± 1.72 | 3.30 ± 0.80 | 3.55 ± 1.25 | 3.92 ± 2.11 |
| TC (mmol/L) | 5.56 ± 0.76 | 5.94 ± 1.07 | 5.90 ± 1.21 | 6.19 ± 1.11 | 5.98 ± 0.92 | 6.15 ± 1.09 |
| HDL-C (mmol/L) | 1.90 ± 0.39 | 1.87 ± 0.44 | 1.97 ± 0.46 | 2.24 ± 0.71 | 2.06 ± 0.40 | 2.08 ± 0.54 |
| LDL-C (mmol/L) | 2.75 ± 0.68 | 2.94 ± 0.88 | 2.94 ± 0.93 | 3.19 ± 0.80 | 3.22 ± 1.68 | 3.07 ± 0.91 |
| non-HDLC (mmol/L) | 3.79 ± 0.68 | 4.14 ± 0.93 | 4.02 ± 1.06 | 4.14 ± 0.76 | 3.97 ± 0.93 | 4.40 ± 1.96 |
| Atherogenic index | 2.03 ± 0.64 | 2.34 ± 0.89a,* | 2.07 ± 0.63 | 1.87 ± 0.64 | 2.02 ± 0.73 | 2.16 ± 0.72 |
| TG/HDL-C | 2.12 ± 0.91 | 2.72 ± 2.46 | 2.16 ± 1.05 | 1.58 ± 0.58 | 1.87 ± 0.78 | 2.11 ± 1.23 |
| apoA1(g/L) | 2.24 ± 0.27 | 2.30 ± 0.38 | 2.29 ± 0.37 | 2.31 ± 0.36 | 2.31 ± 0.37 | 2.32 ± 0.40 |
| apoB (g/L) | 1.09 ± 0.22 | 1.19 ± 0.26 | 1.17 ± 0.28 | 1.20 ± 0.23 | 1.16 ± 0.22 | 1.21 ± 0.26 |
| apoB/apoA1 ratio | 0.54 ± 0.13 | 0.57 ± 0.13 | 0.57 ± 0.15 | 0.54 ± 0.11 | 0.55 ± 0.13 | 0.59 ± 0.14 |
a
compared with GG genotype carriers in the same group, *p < 0.05, **p < 0.01.